| Dr Aerial A Avery, DPM | |
|
1921 Stonecipher Dr, Ada, OK 74820-3439 | |
| (580) 436-3980 | |
| (580) 421-6283 |
| Full Name | Dr Aerial A Avery |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 18 Years |
| Location | 1921 Stonecipher Dr, Ada, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194915538 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 0103301002 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chickasaw Nation Medical Center | Ada, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chickasaw Nation Division Of Health | 8426957523 | 209 |
News Archive
A new study published Tuesday 10 March, No Smoking Day, from King's College London highlights the 'clear benefit' of using e-cigarettes daily in order to quit smoking, and supports their effectiveness when compared to other methods of quitting, including nicotine replacement therapy or medication.
With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter for Solesta® as a treatment for fecal (bowel) incontinence.
AGTC, a privately held company, and Icagen, Inc. today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to patents relating to the ion channel gene CNGB3, which has been linked to certain disorders of the eye. Under the terms of the agreement, Icagen has assigned ownership of the patents to AGTC, which intends to use the patented technology for gene therapy as a potential treatment for Achromatopsia, a severe form of daytime blindness.
MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the leading medical journal Science.
› Verified 7 days ago
| Provider Name | Chickasaw Nation Division Of Health |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1255364923 PECOS PAC ID: 8426957523 Enrollment ID: O20040108000364 |
News Archive
A new study published Tuesday 10 March, No Smoking Day, from King's College London highlights the 'clear benefit' of using e-cigarettes daily in order to quit smoking, and supports their effectiveness when compared to other methods of quitting, including nicotine replacement therapy or medication.
With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter for Solesta® as a treatment for fecal (bowel) incontinence.
AGTC, a privately held company, and Icagen, Inc. today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to patents relating to the ion channel gene CNGB3, which has been linked to certain disorders of the eye. Under the terms of the agreement, Icagen has assigned ownership of the patents to AGTC, which intends to use the patented technology for gene therapy as a potential treatment for Achromatopsia, a severe form of daytime blindness.
MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the leading medical journal Science.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Aerial A Avery, DPM 1921 Stonecipher Dr, Ada, OK 74820-3439 Ph: (580) 436-3980 | Dr Aerial A Avery, DPM 1921 Stonecipher Dr, Ada, OK 74820-3439 Ph: (580) 436-3980 |
News Archive
A new study published Tuesday 10 March, No Smoking Day, from King's College London highlights the 'clear benefit' of using e-cigarettes daily in order to quit smoking, and supports their effectiveness when compared to other methods of quitting, including nicotine replacement therapy or medication.
With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter for Solesta® as a treatment for fecal (bowel) incontinence.
AGTC, a privately held company, and Icagen, Inc. today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to patents relating to the ion channel gene CNGB3, which has been linked to certain disorders of the eye. Under the terms of the agreement, Icagen has assigned ownership of the patents to AGTC, which intends to use the patented technology for gene therapy as a potential treatment for Achromatopsia, a severe form of daytime blindness.
MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the leading medical journal Science.
› Verified 7 days ago
Dr. Bryan Andrew Blanck, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1631 Arlington St, Ada, OK 74820 Phone: 580-559-0001 Fax: 580-559-0002 | |
Dr. Melissa Lynn Adams, D.P.M Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 905 Colony Dr, Ada, OK 74820 Phone: 580-436-5111 | |
Foot & Ankle Surgeons Of Oklahoma Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 1201 Arlington St Ste C, Ada, OK 74820 Phone: 580-332-3399 | |
Dr. Jon M Humphers, D.P.M Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Dr, Ada, OK 74820 Phone: 580-436-3980 Fax: 580-421-6205 |